Alcohol use disorder can be improved without quitting through behavioural harm-reduction: Lancet

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-03-18 01:15 GMT   |   Update On 2021-03-18 07:16 GMT
Advertisement

USA: Combined behavioural harm-reduction and pharmacological treatment can reduce alcohol use and alcohol-related harm without having to quit or abstain from alcohol, finds a recent study in the journal Lancet Psychiatry. The treatment given for 12-weeks to in people experiencing homelessness and alcohol use disorder also improved physical health-related quality of life.

The researchers also found not consistent but positive findings for behavioural harm-reduction treatment alone. Harm-reduction is a treatment that aims to incrementally reduce alcohol-related harm and improve health-related quality of life without requiring abstinence.

"In people experiencing homelessness and alcohol use disorder, the rate of alcohol-related mortality is high and calls for effective and accessible treatment. However, typical abstinence-based treatments does not engage this population," wrote the authors. "Recent studies have shown the effectiveness and acceptability of harm-reduction in this population. Harm-reduction is a treatment that aims to incrementally reduce alcohol-related harm and improve health-related quality of life without requiring abstinence." 

Prof Susan E Collins, University of Washington School of Medicine, Seattle, WA, USA, and colleagues aimed to test the efficacy of combined pharmacological and behavioural harm-reduction treatment for alcohol use disorder (HaRT-A) in people experiencing homelessness and alcohol use disorder. 

For the purpose, the researchers conducted a randomised clinical trial at three community-based service sites in Seattle, WA, USA. It included 308 adults (aged 21–65 years) who met the DSM-IV-TR criteria for alcohol use disorder and who experienced homelessness in the past year. They were randomly assigned in the ratio 1:1:1:1 to receive either HaRT-A plus intramuscular injections of 380 mg extended-release naltrexone (XR-NTX; HaRT-A plus XR-NTX group, n=74); HaRT-A plus placebo injection (HaRT-A plus placebo group, n=78); HaRT-A alone (HaRT-A alone group, n=79); or community-based supportive services as usual (services-as-usual control group, n=77).

Patients assigned to receive HaRT-A attended sessions at baseline (week 0) and in weeks 1, 4, 8, and 12. XR-NTX and placebo injections were administered in weeks 0, 4, and 8.  All participants were invited to follow-up assessments at weeks 4, 8, 12, 24, and 36.

The primary outcomes were self-reported alcohol use quantity (ie, alcohol quantity consumed on peak drinking occasion, as measured with the Alcohol Quantity Use Assessment questionnaire) and frequency (measured with the Addiction Severity Index), alcohol-related harm (measured with the Short Inventory of Problems-2R questionnaire), and physical and mental health-related quality of life (measured with the Short Form-12 survey). 

Using piecewise growth modelling and an intention-to-treat model, the researchers compared the effects of the three active treatment groups with the services-as-usual control group, and the HaRT-A plus XR-NTX group with the HaRT-A plus placebo group, over the 12-week treatment course and during the 24 weeks following treatment withdrawal. 

Key findings of the study include:

  • Compared with the services-as-usual control group, the HaRT-A plus XR-NTX group showed significant improvements from baseline to 12 weeks post-treatment across four of the five primary outcomes: peak alcohol quantity (linear B −0·48; full model Cohen's d=–0·68), alcohol frequency (linear B −4·42; full model Cohen's d=–0·16), alcohol-related harm (linear B −2·22; full model Cohen's d=–0·56), and physical health-related quality of life (linear B 0·66; full model Cohen's d=0·43).
  • Compared with the services-as-usual control group, the HaRT-A plus placebo group showed significant improvements in three of the five primary outcomes: peak alcohol quantity (linear B −0·41; full model Cohen's d=–0·23), alcohol frequency (linear B −5·95; full model Cohen's d=–0·13), and physical health-related quality of life (linear B 0·53; full model Cohen's d=0·35).
  • Compared with the services-as-usual control group, the HaRT-A alone group showed significant improvements in two of the five primary outcomes: alcohol-related harm (linear B −1·58; full model Cohen's d=–0·40) and physical health-related quality of life (linear B 0·63; full model Cohen's d=0·41).
  • After treatment discontinuation at 12 weeks, the active treatment groups plateaued, whereas the services-as-usual group showed improvements. Thus, during the post-treatment period (weeks 12 to 36), the services-as-usual control group showed greater reductions in alcohol-related harm compared with both the HaRT-A plus XR-NTX group (linear B 0·96; full model Cohen's d=0·24) and the HaRT-A alone group (linear B 1·02; full model Cohen's d=0·26).
  • During the post-treatment period, the services-as-usual control group significantly improved on mental health-related quality of life compared with the HaRT-A alone group (linear B −0·46; full model Cohen's d=–0·28), and on physical health-related quality of life compared with the HaRT-A plus XR-NTX group (linear B −0·42; full model Cohen's d=–0·27), the HaRT-A plus placebo group (linear B −0·42; full model Cohen's d=–0·27), and the HaRT-A alone group (linear B −0·47; full model Cohen's d=–0·31).
  • For all other primary outcomes, there were no significant linear differences between the services-as-usual and active treatment groups.
  • When comparing the HaRT-A plus placebo group with the HaRT-A plus XR-NTX group, there were no significant differences for any of the primary outcomes.
  • Missing data analysis indicated that participants were more likely to drop out in the services-as-usual control group than in the active treatment groups; however, primary outcome findings were found to be robust to attrition.
  • Participants in the HaRT-A plus XR-NTX, HaRT-A plus placebo, and HaRT-A alone groups were not more likely to experience adverse events than those in the services-as-usual control group.

"Considering the non-significant differences between participants receiving HaRT-A plus placebo and HaRT-A plus XR-NTX, the combined pharmacological and behavioural treatment effect cannot be attributed to XR-NTX alone," wrote the authors. "Future studies are needed to further investigate the relative contributions of the pharmacological and behavioural components of harm-reduction treatment for alcohol use disorder, and to ascertain whether a maintenance treatment approach could extend these positive outcome trajectories." 

The study titled, "Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial," is published in the journal Lancet Psychiatry.

DOI: https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(20)30489-2/fulltext

Tags:    
Article Source : Lancet Psychiatry

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News